The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Market Size Is Forecasted For The Methenamine Hippurate Tablets Market By 2030 Based On Its 2026 Value?
The methenamine hippurate tablets market size has demonstrated strong growth in recent years. It is expected to expand from $10.11 billion in 2025 to $10.86 billion in 2026, at a compound annual growth rate (CAGR) of 7.4%. The historical period’s growth can be linked to limited awareness regarding recurrent UTI prevention, restricted access to specialized urology care, low adoption of antimicrobial tablets, reliance on hospital-based treatment, and traditional packaging formats.
The methenamine hippurate tablets market is anticipated to show robust expansion over the next few years. It is expected to achieve a value of $14.49 billion by 2030, progressing at a compound annual growth rate (CAGR) of 7.5%. This projected growth is primarily due to the increasing frequency of urinary tract infections, a rising demand for outpatient and homecare medical attention, innovations in tablet formulation technology, greater adoption of personalized medicine approaches, and the widening reach of online pharmacy channels. Significant trends for the forecast period encompass a growing incidence of recurrent UTIs, an expanding global geriatric population, a heightened preference for oral antimicrobial therapies, the broadening of home healthcare provisions, and the advent of individualized medication regimens.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9412&type=smp
What Key Growth Drivers Are Influencing The Methenamine Hippurate Tablets Market?
The increasing prevalence of urinary tract infections (UTI) is anticipated to stimulate the future growth of the methenamine hippurate tablets market. Urinary tract infections are prevalent conditions that develop when bacteria, typically from the skin or rectum, enter the urethra and infect the urinary tract. Methenamine hippurate tablets are utilized for the prevention or treatment of recurrent urinary tract infections caused by specific bacterial strains. For instance, in October 2023, the National Health Service, a UK-based government department, reported 147,285 admissions with urinary tract infections (UTIs) as the main diagnosis during the 2022-23 period. Among these, 56% (82,392) were individuals aged 65 and older, with the highest number of admissions, 17,280, occurring in the 80-84 age group. Consequently, the escalating instances of urinary tract infections are a key factor driving the expansion of the methenamine hippurate market.
What Segment Categories Are Evaluated In The Methenamine Hippurate Tablets Market Study?
The methenamine hippurate tablets market covered in this report is segmented –
1) By Type: 20 Tablets Or Bottle, 6 Tablets Or Bottle
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
3) By Application: Uncomplicated UTIs, Healthcare-associated UTIs
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By 20 Tablets per Bottle: Standard Packaging, Bulk Packaging Options
2) By 6 Tablets per Bottle: Standard Packaging, Sample Or Trial Packaging
What Trends Are Influencing The Methenamine Hippurate Tablets Market Outlook?
Leading companies in the methenamine hippurate tablets market are engaging in collaborations to enhance their market profitability. Such strategic cooperation involves deliberate partnerships between entities, aimed at achieving common goals through synchronized efforts and by leveraging each other’s unique strengths and resources. For example, in May 2023, EQL Pharma AB, a Sweden-based pharmaceutical provider of methenamine hippurate tablets, formed an alliance with Dr. Pfleger Arzneimittel GmbH. This partnership is designed to allow EQL Pharma AB to introduce Methenamine Hippurate under an EQL-registered brand within the subsequent two years, incorporating standard license fees, specific regulatory and reimbursement milestones, and a supply price contingent on volume, upon obtaining regulatory approval. Dr. Pfleger Arzneimittel GmbH operates as a pharmaceutical company located in Germany.
Which Companies Are Influencing The Methenamine Hippurate Tablets Market?
Major companies operating in the methenamine hippurate tablets market are Alvogen Lux Holdings S.ÀR.L., Micro Labs Inc., Aurobindo Pharma, Amneal Pharmaceuticals Inc., Viatris Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Dr. Reddy’s Laboratories Ltd., Cadila Healthcare Ltd., Torrent Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Zydus Pharmaceuticals Ltd., Lupin Ltd., Alkem Laboratories Ltd., Ipca Laboratories Ltd., Granules India Ltd., Teva Pharmaceutical Industries Ltd., Apotex Pharmachem Inc., Sandoz International GmbH, Mylan Laboratories Ltd.
Access The Complete Methenamine Hippurate Tablets Market Report:
https://www.thebusinessresearchcompany.com/report/methenamine-hippurate-tablets-global-market-report
Which Region Contributes The Most To The Methenamine Hippurate Tablets Market?
North America was the largest region in the methenamine hippurate tablets market in 2025. The regions covered in the methenamine hippurate tablets market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Methenamine Hippurate Tablets Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=9412&type=smp
Browse Through More Reports Similar to the Global Methenamine Hippurate Tablets Market 2026, By The Business Research Company
Methenamine Hippurate Tablets Market Report 2026
https://www.thebusinessresearchcompany.com/report/methenamine-hippurate-tablets-global-market-report
Methicillin Resistant Staphylococcus Aureus Mrsa Drugs Market Report 2026
Muscle Relaxant Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/muscle-relaxant-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model